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1. Abstract 
When facing such a common condition as hypertension, it is common to take the 
environmental and lifestyle factors into account as an etiology, paying less 
attention to partially or fully genetic forms of hypertension. This review aims to 
summarize and describe each of the rare but already known monogenic 
syndromes and to inform of the current state of the undergoing research 
regarding polygenic forms of hypertension, in which great progress is being 
made thanks to genome wide association studies. In monogenic hypertension 
most of the pathophysiology is already known, with direct consequences of 
improvement in the areas of diagnose and treatment; on polygenic hypertension 
however, there is still a road ahead before reaching clinical applicability on a 
large scale. 
2. Methods 
Systematic review of scientific papers searching in PubMed, UpToDate and The 
Cochrane Library Plus, without date limit, taking into account papers written in 
English and Spanish. The Guidelines of both European and American heart 
associations were also reviewed. Abstract and full articles were reviewed 
according to the necessities. 
3. Key words 
 Genetic hypertension, essential hypertension, monogenic hypertension. 
 
Resumen 
 Ante una patología tan extensa y cotidiana como la hipertensión, es común que 
se piense en los factores relativos al estilo de vida como etiología, dejando de lado las 
etiologías pura o parcialmente genéticas. El objetivo de este trabajo es recopilar 
información acerca de los ya conocidos pero poco frecuentes síndromes monogénicos, 
así como informar sobre el estado actual de la investigación en el campo de las formas 
poligénicas de la hipertension 
 Métodología: Revisión sistemática de artículos científicos consultando las bases 
de datos Pubmed, Uptodate y The Cochrane Library Plus, sin restricción de fecha, en los 
idiomas español e inglés. Se revisaron también guías de las sociedades europea y 
americana de cardiología. Se revisaron abstracts y en los casos necesarios los artículos 
completos. 
 Palabras clave: Hipertensión genética, hipertensión esencial, hipertensión 
monogénica. 
  
4. Introduction 
 
  Arterial hypertension (HT) has a high prevalence and is a major risk factor for the 
development of cardiovascular diseases. It is a major contributor to worldwide 
morbidity and mortality and hence poses a huge socioeconomic burden(1).  There is a 
direct relationship between the incidence of high blood pressure (HBP) and the 
complications and diseases attributable to this incidence(2). However the threshold to 
diagnose a patient with HT has shifted during the years. The European Society of 
Cardiology sets the cutting points for HT diagnose at 140mmHg for systolic arterial 
pressure and/or at 90mmHg for diastolic arterial pressure(3), while the American Heart 
Association sets the bar at 130mmHg for systolic arterial pressure and/o at 80mmHg for 
diastolic arterial pressure(4). Nevertheless, both Associations agree that the threshold 
to start treatment should be the one the Europeans set for diagnose. 
 
 The estimated prevalence of HT in 2015 was of 1.13 billion, which translates into 
roughly 30% of the adult population worldwide(5),(6). This prevalence, although with 
some variations between countries, could be considered global even taking into 
consideration the economical differences across the globe(5). HT prevalence 
experiments an increase related to ageing, getting more and more common in the older 
age groups. People above 60 years old have a prevalence of HT larger than 60%(5). 
According to the way the global population is currently ageing, adapting a more 
sedentary lifestyle and increasing in body mass, future estimations point to a 15-20% 
increase in the HT prevalence by 2025. Thus, around 1.5 billion people will suffer from 
HT(7). 
 
 HBP was the main responsible for premature death in 2015 at a global scale.With 
almost 10 million premature deaths, and 200 million disability adjusted lost years 
(DALYs). HBP it is the leading cause in both categories(8). Despite the improvements that 
the fields of diagnose and treatment have experienced in the past 30 years, the DALYs 
attributable to HT have increased 40% since 1990(8). The most important factor when 
it comes to mortality and disabilities is the increase of the systolic blood pressure over 
140mmHg. This factor is accountable for most of the HT related deaths, which include: 
4,9 million deaths by ischemic heart disease, 2 million deaths by hemorrhagic stroke and 
1,5 million deaths by ischemic stroke(8). 
 
 Despite being an asymptomatic and easily detectable disease, HT can cause 
severe and even lethal complications. The HT affected organs are mainly the heart, 
arteries, the kidneys, the brain and the retinas.  
 At cardiac level, chronically increased left ventricular workload in hypertensive 
patients can result in left ventricular hypertrophy, impaired left ventricle relaxation, left 
atrial enlargement, an increased risk of arrhythmias, especially atrial fibrillation (AF), and 
an increased risk of heart failure with preserved ejection fraction and heart failure with 
reduced ejection fraction(3). 
 At arterial level, HT can cause harm by altering the blood flow at both 
macrovascular and microvascular levels, causing endothelial dysfunction and arterial 
wall remodeling. These changes increase the risk of plaque formation and subsequently 
the risk of stroke. Thickening of the arterial wall increases the risk of ischemic conditions. 
In big arteries these changes cause stiffness, which is the pathophysiological basis of 
isolated systolic hypertension and is also related to multiple cardiovascular 
complications(3). 
 In the kidney, HT is the second leading cause of chronic kidney disease after 
diabetes mellitus. Among the injuries that HT can cause in the kidney we can find: 
tubulointerstitial necrosis, focal and diffuse glomerulosclerosis with loss of nephrons, 
chronic renal ischemia due to atherosclerosis, renal infarction or embolism; all of them 
leading to chronic renal failure. The pathophysiology behind renal damage and HT is a 
vicious circle of Na+ and volume reabsorption (3). 
 The brain on a patient with HBP is more at risk of suffering cerebrovascular 
diseases such as lacunar infarctions, intracerebral hematomas or thrombotic or embolic 
strokes. Besides, other HT manifestations at a central nervous system level include 
hypertensive encephalopathy, vascular dementia or microvascular brain damage(3). 
 In the retina HT can cause optic neuropathy, choroidopathy and most commonly, 
hypertensive retinopathy. In hypertensive retinopathy the increase of intraarteriolar 
pressure leads to endothelial disfunction, which causes plasma exudates in the vascular 
wall, causing greater luminal narrowing, which ends up producing fibrinous necrosis and 
papilledema that can cause blindness(3). 
 
 
 
 
 
 
 
 
 
 
5. Ethiological Classification 
 
Most HT results from a combination 
of behavioral and environmental 
factors as seen in Figure 1(4). 
However, various genetic mutations 
have been identified as distinct 
causes as well. These genetic forms 
of hypertension stem from gain- or 
loss-of-function mutations within the 
mineralocorticoid, glucocorticoid, or 
sympathetic pathways(9). As a 
general way of classification, every 
genetic form of HT can be fitted into 
one of these 2large groups: primary 
(or essential) hypertension and 
secondary hypertension (10). 
  
Essential hypertension is the HT 
that by definition has no 
identifiable cause, while secondary 
HT is the result of an identifiable 
cause.  The majority of hypertension (90-95%) falls under the definition of essential 
hypertension(11). Essential hypertension has traditionally been categorized as 
idiopathic, however this is only partially true because we are starting to have more and 
more information on genetic variations or genes that are overexpressed or 
underexpressed as well as the intermediary phenotypes that they regulate to cause high 
BP(12). Several  environmental factors are known to increase blood pressure, including 
obesity, insulin resistance, high alcohol intake, high salt intake (in salt-sensitive 
patients), aging, sedentary lifestyle, stress, low potassium intake, and low calcium 
intake, all of them can be purely environmental but they can all also be influenced by 
genetic predisposition. Furthermore, many of these factors are additive, such as obesity 
and alcohol intake(13), (14). 
  
When it comes to the role of genetics in the heritability of HT, there are two main 
groups, polygenic and monogenic forms of HT. 
Figure 1. Venn diagram of the different factors associated with HT. 
Taken from(4). 
 The term, monogenic hypertension, is 
used to describe specific genetic hypertensive 
disorders which inhibit normal renal and/or 
adrenal blood pressure regulation. It is 
especially important to keep these rare 
conditions in mind when diagnosing HT in 
children, as the younger the child, the more 
likely that their hypertension is due to a 
secondary cause. Recent advancements in 
genetic sequencing methodology have provided 
further insight into these conditions(15). This 
means that monogenic forms of HT are well 
established rare syndromes, in which the 
diagnostic suspicion plays a main role since 
effective treatment is available. These 
syndromes are listed on table 1, which also 
classifies them according to their renin and 
aldosterone levels(15).  
On the other hand, polygenic HT is still much 
less clear. It is believed that essential hypertension is really polygenic, but there is still 
much research to be done. As of today, there are more than 50 different genes that have 
been linked to an increased risk of HT, and the list is still growing. The implementation 
of genome-wide association studies (GWAS) is responsible for many of these new 
findings(16). 
 
 In secondary HT there is a clear underlying cause that is recognized to be 
responsible for the HBP. The most common causes of secondary HT are: renal 
parenchymal disease, renovascular disease, primary aldosteronism, obstructive sleep 
apnea and drug or alcohol induced HT(4). There are even more causes that have been 
found to cause secondary HT butthey are beyond the scope of this review, which focuses 
on the genetic aspects of essential HT, both polygenic and monogenic. 
 
 
 
 
 
 
 
TABLE 1. Basic classification scheme for causes of 
monogenic hypertension. Taken from (15) 
6. Genetics in Essential HT 
a. Monogenic 
Hypertension 
 
 
As seen on table 2(15), monogenic forms 
of hypertension are conformed by 11 well 
stablished syndromes, which all have the 
increase of blood Na+ absorption and the 
early onset of HT in common, but this 
comes because of different mechanisms. 
All these syndromes present low renin 
levels, but they can be further classified 
regarding aldosterone levels. 
Low aldosterone syndromes include Liddle 
syndrome, congenital adrenal hyperplasia 
and apparent mineralocorticoid excess. 
Gordon syndrome or pseudo 
hypoaldosteronism type II have normal 
levels of aldosterone. The remaining 
familial hypoaldosteronisms (types I, II, III 
and IV) present themselves with high 
aldosterone levels, while familial 
pheochromocytoma and hypertension and 
brachydactyly syndrome fall outside of this 
classification as their pathophysiological 
pathways don’t involve the renin-
angiotensin-aldosterone chain. 
All these 10 syndromes are explained 
more in depth in the following sections. 
 
 
 
 
 
TABLE 2 Monogenic forms of hypertension with involved 
genotypes. Taken from (15) 
i. Liddle syndrome 
Liddle syndrome was thought to only be 
caused by an autosomal dominant (AD) 
mutation which consists of a gain-of-function 
mutation β- or γ-subunit of the epithelial 
sodium channel present in the collecting duct, 
however, recent studies confirmed that a 
mutation in the -subunit (while β- and γ-
subunits were nonmutated)  has also been 
found to cause this syndrome, this mutation is 
a missense mutation, as depicted on Figure 
3(17). The cytogenetic locus of this mutation is 
12p13.31 for SCNN1A(OMIM 600228), 
16p12.2 (OMIM 177200) for SCNN1B and 
SCNN1G (OMIM 600761). The epithelial 
sodium channel´s alpha, beta and gamma subunits,SCNNA1 SCNN1B and SCNN1G, 
respectively, are most commonly affected (18). The disfunction of SCNN1B and SCNN1G 
results in disruption of the regulation of the process necessary to break down epithelial 
sodium channels (via disruption of  expression of proline-rich regions of the cytoplasmic 
carboxyl terminus and results in loss of regulatory binding sites for Nedd4-2, a ubiquitin 
ligase that is in charge of the epithelial sodium channel breakdown)(19). This leads to an 
excess of sodium reabsorption (gain of function) which ultimately leads to this form of 
genetic monogenic hypertension. 
 
The excess of Na+ reabsorption responds only to the mutation of the epithelial Na 
channel, so the renin aldosterone hormonal axis tries to correct this, thus, both renin 
and aldosterone present low levels in this syndrome in an attempt to lower the blood 
Na+ concentration(20). The continuous reabsorption of Na+ is also responsible for the 
hypokalemia, as the Na+ carries the K+ extrusion with it via the Na+/K-ATPase pump on 
the alpha-intercalated cells(18). This exact mechanism is also the key to explain the mild 
metabolic alkalosis that appears in Liddle Syndrome, as the increased Na+ reabsorption 
increases the net negativity of the lumen, causing an increase in H+ extrusion via the 
renal outer medullary potassium channel and H+-ATPase pump, also  located on alpha-
intercalated cells(21). 
 
Liddle syndrome is an extremely rare disease, with only 31 new formal diagnoses 
registered since 2008. However it is considered as an underrecognized, and thus 
underdiagnosed, cause of HT by many nephrologists(22). The age of onset of the HT in 
Liddle syndrome patients varies between late childhood and adolescence(23). Some of 
those 30 cases have appeared without a family history, indicating a possible 
spontaneous mutation which lead to the syndrome, this supports the advice of including 
Liddle´s syndrome in every early onset HT´s differential diagnosis(23). Even though 
Liddle´s can be suspected in a patient with story of familiar HT with low renin and 
Figure 3: Causes and genetics of Liddle syndrome (17). 
aldosterone levels, the definitive diagnosis requires genetic testing for SCNN1B, SCNN1A 
and SCNN1G(24). Liddle syndrome is alternatively known as pseudohyperaldosteronism 
due to its similarity to hyperaldosteronism with hypertension, hypokalemia, and 
metabolic alkalosis(25). 
To treat Liddle´s syndrome, diuretics that target the renin-aldosterone axis, such 
as spironolactone, have proven to be ineffective because in Liddle´s the effect of this 
axis is not responsible for the augmented Na reabsorption(26). Instead potassium 
sparring diuretics such as amiloride (only option during pregnancy) or triamterene show 
great results in keeping the HT in Liddle´s under control-These types of diuretics 
specifically target the epithelial Na+ channels, inhibiting them, thus counteracting the 
effect of the mutation of SCNN1B and SCNN1G, which is the pathophysiological basis of 
HT in Liddle´s syndrome(27). A low Na+ intake is also part of the treatment and 
management of Liddle´s, as is it in most cases of HT(23). The mechanism of the 
treatment is shown in Figure 4(15). 
 
Figure 4: Treatment of Liddle´s syndrome(15). 
 
ii.Congenital adrenal hyperplasia 
Congenital adrenal hyperplasia or CAH encompasses several autosomal recessive 
diseases that result from gene mutations for enzymes that mediate the biochemical 
steps of production of mineralocorticoids, glucocorticoids or sex steroids from 
cholesterol by the adrenal glands(28). Though 21a-hydroxylase deficiency is the most 
common, 11b-hydroxylase deficiency (11OHD or CAH type IV) and 17a-hydroxylase 
deficiency (17OHD or CAH type V), are two subtypes of CAH known to cause monogenic 
hypertension, so they will be reviewed more in depth than the others(29). The 
respective enzymes regulate different steps in steroid synthesis, but 11OHD and 17OHD 
deficiency both cause elevated deoxycortisol and deoxycorticosterone levels. These 
intermediates have activity at the mineralocorticoid receptors. The overactivation of 
these receptors leads to HT and hyperkalemia. Both 11b-hydroxylase deficiency and 
17a-hydroxylase deficiency are inherited in autosomal recessive fashion, which come 
from inactivating mutations that prevent the expression of these respective 
enzymes(30). In the Figure 5(15) the normal synthesis of mineralocorticoids is depicted 
to visualize where the mentioned enzymes take part. These metabolites are active at 
the mineralocorticoid receptor and are important in generating hypertension(15).  
 
Figure 5: Steroidogenesis Pathways. The orange arrows show the activity of 11b-
hydroxylase (deficient 1 in type IV) while the orange rectangle surrounds the steroid 
hormones still produced in CAH type IV. The green arrows denote the activity of 17a-
hydroxylase (deficient in type V) while the green rectangle encircles those hormones 
produced in CAH type V. ACTH - adrenocorticotropic hormone; DHEA - 
dihydroepiandrosterone. (15).  
 
 
a. 11-Hydroxylase deficiency (CAH-IV) 
Absence or malfunction of 11b-Hydroxylase prevents the conversion of 
deoxycortisone and deoxycortisol into corticosterone and cortisol, respectively (Figure 
5). Both deoxycortisone and deoxycortisol accumulate and even though they have weak 
activity at the mineralocorticoid receptor, the amount of metabolite ends up being 
enough to cause to produce a significant mineralocorticoid activity that leads to HT. As 
the conversion to glucocorticoids, androgens and estrogens are preserved, patients 
present high levels of deoxycorticosterone, deoxycoritsol and androgens, mainly 
androstenedione and dehydroepiandrosterone, which is key for diagnostic purposes. 
The diagnostic test used for this is stimulation of the axis with ACTH (adrenocorticotropic 
hormone) as high levels of the androgens coupled with HTN prove helpful in 
differentiating 11b-Hydroxylase deficiency from other causes of CAH and monogenic 
hypertension(31). Prenatal diagnose is available by measuring 11b-Hydroxilase activity 
in amniotic urine(32), but the confirmatory diagnose is made by a sequencing  test for 
the CYP11B1 gene (cytogenetic locus 8q24.3)(31). 
11bHydroxylase deficiency is a rare condition that accounts for 5-8%of the CAH 
CAH IV CAH V 
cases(33). Its prevalence rises to a 15% of CAH cases in certain populations such as 
Muslim Jewish or middle eastern populations(34). 
As the key step to form sexual hormones is also affected in this syndrome, CAH-
IV patients present sexual development disorders, which can be found at birth. If the 
patient is a female the androgen accumulation will provoke a virilization, presenting 
ambiguous genitalia with enlarged clitoral fold at rest.(9) Both females and males will 
experience precocious puberty and hypertension onset at young ages.  
Treatment consists of glucocorticoids in sufficient doses to lower ACTH secretion, 
inhibiting stimulation of steroid synthesis and accumulation of mineralocorticoid 
receptor agonists. Spironolactone, amiloride, and calcium channel blockers may be 
further used to treat hypertension. Further considerations include individualized 
therapy to accommodate sexual development, specifically in patients with genital 
malformations, it is more often females the ones who may need surgical correction(35). 
 
b. 17-Hydroxylase deficiency (CAH-V) 
Also known as P450C17a deficiency, is caused by a mutation on gene CYP17A1, 
on cytogenetic locus 10q24.32 which encodes the said enzyme. This enzyme has two 
key actions: 17-hydroxylase and 17,20-lyase activity (31). Its 17-hydroxylase function 
generates 17-hydroxypregnenolone and 17-Hydroxyprogesterone, which can be 
converted to cortisol. These products of the 17-Hydroxylase are also substrates for the 
17,20-Lyase activity, which generates DHEA and androstenedione to serve as precursors 
for androgen and estrogen synthesis. This rare disorder thus blocks the production of 
cortisol as its direct precursors are not synthesized, shifting steroid production toward 
the mineralocorticoids (Figure 5). Since the blockage is so early in the pathway, there is 
very little production of sex hormones(34). Clinically it manifests as hypogonadism, 
hypokalemia and HT. In males CAH-V causes ambiguity of the external genitalia and 
might even present a female phenotype in the external sexual organs. In females it 
causes primary amenorrhea and delayed sexual development or it may present solely 
as infertility(36),(37).  
 As a diagnostic approach, patients with early onset HT and hypogonadism should 
be tested using ACTH stimulation, which to be positive for 17-Hydroxylase deficiency 
would need to show atypically elevated levels of pregnenolone and progesterone 
relative to their next metabolites in the mineralocorticoid synthesis chain (17-
pregnenolone and 17 progesterone respectively). It was believed to be a very rare 
condition, representing less than 1% of CAH but recent studies suggest that it might be 
an underdiagnosed disease(38). 
 The target when treating this disease is the same as for 11Hydroxylase 
deficiency: glucocorticoids in sufficient doses to lower ACTH secretion, inhibiting 
stimulation of steroid synthesis and accumulation of mineralocorticoid receptor 
agonists. Spironolactone, amiloride, and calcium channel blockers may be further used 
to treat hypertension. Addition of sex hormone therapy is also needed, depending of 
the degree of production shown by the serum levels of those hormones(36). 
 
iii. Syndrome of apparent mineralcorticoid excess 
The syndrome of apparent mineralocorticoid excess (AME) is inherited in an autosomal 
recessive fashion. The genetic cause of this syndrome is an inactivating mutation of 11-
Hydroxysteroid dehydrogenase type 2 (HSF11B2), which inactivates cortisol to the less 
active metabolite cortisone. This gene is located on the chromosomal locus 16q22.1(39). 
In physiological conditions the mineralocorticoid receptor´s prototypical ligand is 
aldosterone, but in AME the excess of cortisol is the one that activates this non-selective 
receptor. In individuals without 
pathology cortisol is expressed at 
much higher physiologic levels 
than aldosterone, HSD11B2 
function is critical to maintaining 
proper control over 
mineralocorticoid receptor 
activation. With this mutation, 
cortisol is not metabolized and is 
able to bind to the 
mineralocorticoid receptor, 
leading to aldosterone like effects 
in the kidney(40), as depicted on 
Figure6(36). Excessive 
consumption of licore of 
Carbenoxolone may also induce 
AME, as they have the ability of 
activating the same receptor as 
cortisol does. 
The spectrum of cortisol-
mediated mineralocorticoid activation includes the classical AME syndrome, with 1 in a 
million affected,  to less severe (nonclassic) forms of AME, the latter with a much higher 
prevalence (7.1%) than classic AME but different phenotype and genotype. Nonclassic 
AME (NC-AME) is mainly related to partial 11βHSD2 deficiency associated with genetic 
variations and epigenetic modifications (first hit) and potential additive actions of 
endogenous or exogenous inhibitors and other factors (ie, age, high sodium intake) 
(second hit).(41) 
Diagnose is suspected when hypokalemia, metabolic alkalosis, 
hypoaldosteronemia with hyporeninemia and elevated cortisol to cortisone ratio (in 24h 
urine sample) are found. It is important to discard excess licorice or carbenoloxone 
consumption, as they may mimic the pseudohyperaldosteronism and are easily 
correctable.  
Figure 6: schematic of the pathophysiology of AME. Dashed 
arrow indicates normal binding of cortisol to the 
mineralocorticoid receptor. Orange arrow indicates AME, 
where due to 11b-dehydrogenase deficiency leads to 
increased levels of cortisol-mineralocorticoid receptor binding, 
causing hyperactivity (15). 
Treatment consists of mineralocorticoid receptor antagonists, such as 
spironolactone or eplerenone, along with potential potassium supplements and dietary 
sodium restriction (42). Elevated cortisol levels may further warrant glucorticoid therapy 
to reduce ACTH-stimulated cortisol production and subsequent mineralocorticoid 
receptor stimulation (43). Renal transplantation may be curative in some cases. NC-AME 
condition should benefit from low-sodium and potassium diet recommendations and 
monotherapy with MR antagonists(44). 
iv. Gordon syndrome 
Gordon syndrome, also known as pseudohypoaldosteronism type 2 (PHA2), is a rare 
monogenic form of HT characterized by hyperkalemia, hyperchloremic metabolic 
acidosis and normal or elevated aldosterone levels(45). Four families of genes are 
involved in the pathophysiology of Gordon syndrome: WNK1, WNK4, KLHL3, and CUL3, 
in loci 12p12.3, 17q21.2, 5q31.2, 2q36.2 respectively(46). The first two mutations affect 
the Na+Cl- co-transporter. In WNK1 or WNK4 PHA2 patients, this transporter is not 
properly endocytosed by mediation of the ubiquitination, so it degrades, causing its 
upregulation, which leads to hyperchloremic metabolic acidosis and an increased Na+ 
absorption, responsible for HT. This PAH2 phenotype can be reached through a gain of 
function mutation on WNK4 or through a loss of function mutation in WNK1, this is 
explained because the WNK4 causes Na+ Cl- channel downregulation, an effect inhibited 
by WNK1. KHLHL3 and CUL3 mutations aid WNK4 When stimulating the serum and 
glucocorticoid inducible protein kinase by modifying the E3 ubiquitin ligases  and thus 
altering the Na+ Cl- cotransporter ubiquitination, causing proteosomal degradation of 
the channel which further activates the Sodium Chloride cotransporter(47).  
 Molecular effects mentioned above cause and excessive Cl- reabsorption by the 
Sodium- Chloride cotransporter, which adds to increased Sodium reabsorption further 
by the epithelial Sodium channel, causing hyperkalemia, hyperchloremic metabolic 
acidosis, and normal-to-elevated levels of aldosterone, which are the most common 
clinical features in Gordon syndrome.  HT tends to manifest in adolescence or early 
adulthood, even if cases involving younger patients have been reported. Global 
prevalence is unknown, but it is believed to be larger than the 180 cases that have been 
reported up to this point(48).  
 Diagnosis is made using genetic testing after the clinical features help to suspect 
any monogenic HT. To treat Gordon syndrome, thiazide type diuretics have shown 
promising results, as they inhibit the overactive Sodium-Chloride cotransporter, as 
shown in figure7. As in previous syndromes low Sodium intake is beneficial (15). 
 
Figure 7: Schematic overview of Gordon Syndrome pathophysiology and treatment. NCC: 
Na+ Cl- Cotransporter. DCT: Distal Convoluted Tubule (15). 
v. Familial hyperaldosteronism type I 
Familial hyperaldosteronism type 1 (FHT1), also called glucocorticoid remediable 
aldosteronism, is inherited in autosomal dominant fashion and was the first to be 
discovered out of the familial hyperaldosteronisms(30). The genetic basis of FHT1 lies 
on the 8q24.3, where to adjacent genes are mutated: CYP11B1 and CYP11B2, which 
encode 11-Hydroxylase and aldosterone synthase, respectively. This particular 
mutation consists on an unequal crossover between the 2 mentioned genes, resulting 
in a chimeric variant of both that renders them so that the gene ends up being regulated 
by ACTH instead of by angiotensin 2, while still controlling aldosterone secretion(49). 
The place of aldosterone secretion shifts, because of the mutation from the zona 
glomerulosa to the adrenal zona fasciculata, thus resulting in an ectopic secretion(50). 
 Clinically the ectopic and excessive aldosterone production causes HT and 
hypokalemia, which go along with suppressed renin levels(51). FHT1 typically presents 
during childhood, in the form of severe HT with mild hypokalemia. FHT1 also increases 
the risk of intracerebral hemorrhage, which has a mortality rate of 60%(52). The 
aldosterone/renin activity relation in plasma is higher than 30 in FHT1 (normal <20), 
which orients the diagnosis in young patients with HT and hypokalemia towards this 
syndrome, although the definite diagnose requires genetic testing(53). 
 Treatment of FHT1 consists of inhibiting ACTH, which in this syndrome will 
suppress the ectopic aldosterone secretion, making blood pressure and Potassium levels 
return back to normal.  The drugs that achieve this effect are glucocorticoids at low 
doses, dexamethasone (0.25mg/day) and prednisolone (5mg/day) being the most 
used(49). 
 
vi. Familial hyperaldosteronism type II 
Familial hyperaldosteronism type II or FHT2 is also called non glucocorticoid remediable 
hyperaldosteronism, which is one of the main differences with FHT1(54). The mutation 
responsible for FHT2 is believed to occur in chromosomal locus 3p.27.1, in the CLCN2 
gene, which encodes chloride channel ClC2, and is inherited in an autosomal dominant 
fashion with variable penetrance(55). This mutated channel has been seen to increase 
aldosterone synthase production and aldosterone production in in vitro studies. There 
is also a correlation between FHT2 and bilateral adrenocortical disease or 
adenomas(56). 
 The onset of HT in FHT2 happens during adulthood, and it is clinically 
indistinguishable from non-hereditary primary aldosteronisms(29). Definite diagnose is 
not possible to achieve yet as testing for CLCN2 still needs more work before it can be 
strongly recommended(55). No clear treatment has yet been purposed, but it is known 
that glucocorticoids are not able to revert the syndrome like it happens with 
FHT1.Instead, the mainstream treatment of FHT2 is mineralocorticoid inhibitor therapy, 
with adrenalectomy as a rescue treatment(9). 
vii. Familial hyperaldosteronism type III 
FHT3 or familial hyperaldosteronism type III is inherited in the same autosomal 
dominant fashion as the previous two FHTs, however in this syndrome the responsible 
mutation lies on chromosomal locus 11q.24.3, where it affects the KCNJ5 gene, which 
encodes a potassium channel in the nephron(57). The mutation affects part of the gene 
which encodes an inward rectifier of the Potassium channel, which loses its ion 
specificity and allows Sodium to pass through causing HT(58). The mutation also 
provokes an increased depolarization of the adrenal cortical cells, which translates into 
more expression of aldosterone synthase, which leads to more aldosterone. 
Consequently, and as in both previous forms of FHT renin is low(56). IN epidemiology 
and treatment FHT2 and 3 are practically identical, both provoking maturity onset HT 
and the treatment ranging from mineralocorticoid inhibitors to adrenalectomy 
depending on the severity of the HT. 
 
viii. Familial hyperaldosteronism type IV 
FHT4 is inherited in the same autosomal dominant fashion as the other FHT syndromes. 
In this particular variant the mutation lies in locus 16p13.3, where the gene CACNA1H, 
which in non-pathological conditions encodes a transient Calcium channel located on 
the zona glomerulosa suffers a gin of function mutation, which makes it more likely to 
open at baseline electrochemical activity and to remain open longer once that activation 
takes place(59). The increased inward Calcium flow stimulates adrenocortical cells, 
subsequently activating aldosterone synthase. Treatment has been the same as for both 
previous subtypes of FHT, however new studies suggest a promising clinical response to 
T-Type Calcium channel blocker Mibefradil(60). 
 
 
 
 
 
 
 
 
 
 
ix. Familial pheochromocytoma 
Unlike previous syndromes, HT in familial pheochromocytoma is caused by adrenergic 
or sympathetic excess. Pheochromocytoma is susceptible to be heritable alone or within 
the context of syndromes as Von Hippel-Lindau, Multiple endocrine Neoplasia syndrome 
type 2 or  type 1 Neurofibromatosis among others(61). Pheochromocytomas are tumors 
that arise on the adrenal glands, coming from chromaffin cells. They synthesize 
norepinephrine and epinephrine in paroxysmal fashion, causing episodes of severe HT 
along with symptoms associated with sympathetic nervous hyperactivity(62). Each of 
the aforementioned syndromes is caused by a different mutation; Von Hippel Lindau is 
caused by a mutation on 3p25.3, where a tumor suppressor gene undergoes a loss of 
function mutation, causing not only bilateral pheochromocytomas to appear more 
often, but also increasing the prevalence of other tumors such as retinal and cerebellar 
angiomas, renal and pancreatic cysts, and renal cell carcinomas(63). Multyple Endocrine 
Neoplasia type II is caused by a suppressing mutation of proto-oncogene RET, which is 
located on chromosomal locus 10.11.21. The loss of function of the tumor suppressing 
gene causes not only pheochromocytoma, but it also causes medullary carcinoma of the 
thyroid gland and hyperparathyroidism on its 2A subtype, and increase of medullary 
carcinoma of the thyroid gland along with mucosal neuromas on the 2B subtype(64). In 
type I neurofibromatosis the mutation responsible for pheochromocytoma happens in 
gene NF1, located on 17q11.2 where information to synthesize neurofibromin is 
encoded. Neurofibromin is a negative regulator for the Ras oncogene pathway, and 
when the mutation causes it to loose function, the oncogene proliferates freely(65). 
 50% of pheochromocytomas are caused by sporadic mutations, leaving the other 
50% to autosomal dominant inheritance that takes place in the above mentioned 
syndromes(66).  
  The diagnostic process of a pheochromocytoma consists on clinical 
suspicion, which may vary from the 3 classic symptoms(diaphoresis, headaches and 
elevated heart rate) to any consequence of sympathetic hyperactivity, followed by 
catecholamine and metanephrine measure in 24h urine. If positive computer 
tomography or magnetic resonance imaging are used to locate the tumor, the finding of 
a pheochromocytoma requires genetic testing for the syndromes that may cause it(67). 
 Treatment starts with antihypertensive therapy until removal surgery is 
programmed. The pre-operative medical management consists of alpha-adrenergic 
antagonists as first line, with the option to use beta adrenergic antagonists and/or 
dihydropyridines as supplements. The prognosis is very different for single 
pheochromocytomas and for those in the context of one of the aforementioned 
neoplasic syndromes, being much worse on the later(68). 
 
 
 
x. HT and Brachydactyly syndrome 
HT and brachydactyly syndrome, also known as Bilginturan syndrome and brachydactyly 
typeE, is a rare autosomal dominant disorder which causes severe salt independent, age 
dependent HT, brachydactyly, increased fibroblast growth rate, altered baroreflex and 
an increased incidence of stroke before the age of 50. The cause of these symptoms is a 
mutated PDE3A gene, located on chromosomal locus 12p12.2. This gene encodes a 
cAMP hydrolyzing phosphodiesterase, which suffers a gain of function provoked by the 
mutation and subsequently causes a decrease of cAMP in vascular smooth muscle cells,  
which triggers proliferation(69). The excess of intravascular smooth muscle proliferation 
causes the lumen to narrow, raising blood pressure and thus being responsible for the 
HT. When treating this syndrome the aim is to lower cAMP concentration and this is 
done using Milrinone in high concentrations(70). 
 
 
B. Polygenic Hypertension  
Polygenic hypertension may be the cause of a much greater percentage of hypertension 
than it is thought to be today. Most cases of hypertension are classified as essential 
because the etiologies and underlaying mechanisms remain unknown. A major 
challenge in hypertension investigation is to identify underlaying mechanisms and 
genes, which would allow for personalized medicine regarding diagnosis, treatment and 
prognosis (71).  
i. GWAS generalities 
The most promising technique for this purpose is genome-wide association studies or 
GWAS. GWAS is an observational study of the whole genetic variants of different 
individuals, in association with a concrete trait, which, in this case is hypertension.  In 
GWAS, the focus lies on the variation of single-nucleotide polymorphisms (SNPs) and 
studies links between the different polymorphisms and the consequent phenotype. In 
short, GWAS asks if a certain SNP is found more often than expected in individuals with 
a phenotype of interest. The final objective of GWAS is to use genetic risk factors to 
make predictions about who is or will be at risk of suffering HT and to identify the 
biological underpinnings of susceptibility for developing new prevention and treatment 
strategies. Figure 9 shows the clinical implications of GWAS(16). 
Figure 9: clinical implications of GWAS (16) 
 
The most basic unit of analysis in GWAS are SNPs. SNPs are changes in the DNA sequence 
composed by a single base-pair, they occur with high frequency in the human 
genome(72). For genetic studies purposes, SNP are used as markers of a genomic region, 
as most of them have a minimal impact on biological systems. However this minimal 
impact sometimes does have functional consequences on the form of amino acid 
changes, could affect to mRNA transcript stability or could have an effect on 
transcription factor binding affinity. Being SNPs the most abundant genetic variation in 
the human genome, many SNPs are present in a large proportion of the human 
population(73).  
SNPs typically have two alleles, which means that within a population there are two 
commonly occurring base-pair possibilities for each SNP location. The frequency of a 
SNP is given in terms of the minor allele frequency or the frequency of the less common 
allele. For example, a SNP with a minor allele frequency of 0.40 would imply that 40% of 
a population has allele versus the more common allele (the major allele), which is found 
in 60% of the population. In the genetic literature, the term SNP is generally applied to 
single base-pair changes that are common in the population (at least 1%), while the term 
mutation is used to describe rarer genetic variants, even though at pure genetic level 
they may be the same.The determinant of the nomenclature these changes receive is 
based on the frequency(74). 
When it comes to matching interpreting the minor allele frequency there are many 
possible scenarios and those scenarios are explained by the common disease/common 
variant hypothesis. This hypothesis states that common diseases like HT are likely 
influenced by genetic variation that is also common in the population, and contrarily 
rare diseases are likely to be influenced by rare genetic variation. Thus allele frequency 
and prevalence are correlated. However, this hypothesis has various nuances, one of 
them relates to penetrance or genetic effect. If an allele would have small genetic effect 
or penetrance in a common disorder such as HT, but this common disorder showed 
heritability it must mean that multiple common alleles influence the disease in a small 
degree each(75).  
Taking this hypothesis as true, 
diseases with genetic basis can 
be put on a continuous scale 
that takes into account both 
allele frequency and effect 
size, as seen on figure 9(76). 
HT would be located on the 
bottom right, next to prostate 
cancer, because it has a lot of 
common variants with small 
genetic effect, as opposed to 
Mendelian disorders, for 
example cystic fibrosis, where 
the causing mutation is well 
known. 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Disease association conceptualized in the dimensions of allele 
frequency and effect ratio (76). 
ii. GWAS in HT 
The most recent study “Genome-wide association analysis identifies novel blood 
pressure loci and offers biological insights into cardiovascular risk”(77) dates from 
2017.It shows over 120 loci that have been identified to have weak effect on blood 
pressure. This study was made based on a 140,886 sample of European ancestry, 
extracted from the UK Biobank. 
The analyses carried on that sample included GWAS of Systolic blood pressure (SBP), 
Diastolic blood pressure (DBP) and pulse pressure (PP) for 9.8 million different SNPs on 
240 different loci. Out of those 240, 107 were validated by in silico investigations and 
other posterior studies(78). 75 of those 107 loci were new findings, validated in this 
study with a P<0.01. The remaining 13 loci thought to have impact haven’t been 
confirmed nor unvalidated to this date. 
24 out of the 107 validated loci were 
reported for association with SBP, 41 for 
DBP and 42 for PP as their main trait of 
association, however many loci were 
associated with more than 1 blood pressure 
trait. Figure 10(77) shows how 24 validated 
loci are associated with both SBP and DBP, 
11 with SBP and PP, one locus with DBP and 
PP and four loci (NADK-CPSF3L, GTF2B, 
METTL21A-AC079767.3 and PAX2) with all 
three traits at genome-wide significance.  
Once validated and associated with 
different BP traits, those 107 were further 
investigated, trying to uncover the 
functional mechanism of action that lead 
each of them to increase blood pressure. 
Those investigations were carried out 
using the main methods to uncover gene-
phenotype associations: gene enrichment 
set analysis method, knockout mouse 
method and concordance with previously 
reported loci in the genetic bibliography 
databases.  
Gene enrichment set analysis is a way of extracting the biological insight of RNA and 
DNA, allowing to interpret the expression of genetic data. The method derives its power 
by focusing on gene sets, that is, groups of genes that share common biological function, 
chromosomal location, or regulation and identifies genes that are over-represented in a 
large group  of genes or proteins, thus stablishing an association(79). 
The knockout mouse method is an animal model for research that consists of genetically 
modifying a mouse replacing or disrupting the gene that is meant to be studied so it 
Figure 10: Venn diagram of the 107 validated loci in 
concordance to which blood pressure trait they relate to. Loci 
in bold were previously discovered, but validated by this study 
(77). 
loses its function. By causing the gene to study (locus in this case) to be inactive, 
observing the changes in phenotype that this may produce, the function of said gene 
can be inferred(80). 
In the aforementioned studies, after conducting gene enrichment set analysis, the 107 
validated loci were found to impact in various different targets in the organism, all of 
them causing an increase in blood pressure. Some loci were found to be associated using 
all 3 different methods, but some loci could only be associated to the phenotype using 
1 o 2 of the purposed methods. 
After conducting said studies, 78 of the 107 loci were linked with cardiovascular 
expression, which was the main area of study. Out of those 78 only in 10 loci were all 3 
of the analyzing methods positive. 18 loci were associated to the suspected function by 
2 different methods, 23 were positive for only one method and the remaining 27 
couldn’t be proved to be linked by any of the three methods, however there is an strong 
suspicion based on computer generated simulations. 
The 78 loci that could be 
linked to a phenotype were 
classified in 2 main groups, 
cardiopulmonary and 
vascular, the last one being 
the most common. In the 
vascular section, loci were 
split up according to the layer 
on which they were found to 
have impact. The found loci, 
the affected tissue and 
number of methods via 
which they were linked to 
that impact are summarized 
on figure 11(77). 
 
 
 
 
This study is the most recent up to date and the one with the broader sample. Even with 
those characteristics the authors recognize that it is still underpowered. 
Other GWAS studies that have contributed to the incorporation of new loci for the 
polygenic HT research include “Meta-analysis of genome-wide association studies 
identifies common variants associated with blood pressure variation in east Asians”(81), 
which was conducted on a sample of 19,608 with an east Asian heritage, this study found 
four new loci (ST7L-CAPZA1, FIGN-GRB14, ENPEP and NPR3). “A Genome-Wide 
Figure 11: Summary of the 78 validated loci, to which 
phenotype they were linked and how many types of 
confirmation supported this evidence.(77) 
Association Study of Hypertension and Blood Pressure in African Americans”(82) only 
has a sample of 1,017, which found two new loci SLC24A4 and CACNA1H. However, this 
study is still relevant because it was performed on subjects of African American heritage 
and there are less studies, and in consequence, discovered loci, for African population. 
Those are the main studies in which the latest GWAS in HT review (Wang, 16) bases 
itself. This review recognizes the Warren et al.(77) study as the biggest one up to date 
in the field. Clues for future personalized prevention and treatment of HT were also 
hinted in this review (16), like for example the Uromodulin gene (UMOD), which was 
identified in a case control study. 
The UMOD gene showed a strong association with lower risk of HT(83). Uromodulin, 
also known as Tamm–Horsfall glycoprotein, is a protein that is expressed in the thick 
portion of the ascending Henle loop, among its many functions (crystallization inhibitor, 
defense against uropathogenic bacteria, down regulation of inflamation), that are not 
yet completely understood, lies one in the field of sodium homeostasis, which is the one 
that has been hypothesized to have an effect on HT. A study on mice using the knockout 
method, Uromodulin KO mice had significant upregulation of Na-coupled urate 
transporters Slc5a8 and Slc22a12 as well as sodium-hydrogen exchanger 3 in the 
proximal tubule and elevated serum uric acid and allantoin, this lead to an overall 
increasen of Na+  reabsorption, leading to HT(84). These findings are one the most 
promising among those showed in the latest study recompilation on polygenic HT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
8. Conclusion 
 
There is a considerable difference between available knowledge for monogenic and 
polygenic hypertension. While monogenic causes of HT have been fully uncovered and 
their pathophysiological mechanisms are well understood, polygenic is still in a much 
earlier stage of research, even if promising studies have already been published and 
more are underway. 
Monogenic genetic hypertension should be suspected in in early onset HT and in 
refractory HT after secondary causes have been ruled out. When it comes to 
monogenic HT, all of the syndromes it englobes have low renin, but to reach an 
accurate diagnosis, along with high clinical suspicion additional hormonal and genetic 
tests are required. Appropriate treatment for these syndromes is available and 
effective, so an early diagnose has a huge impact in lowering disease progression and 
minimizing both morbidity and mortality.  Emphasis must be made in the area of 
diagnostic improvement, as these conditions are largely underdiagnosed and many 
patients with monogenic HT are catalogued as non-genetic (classic) HT, thus not 
receiving appropriate treatment. Future research in the field of monogenic HT aims to 
improve diagnosis rate, which relays largely on clinical suspicion by the practitioners.  
 
Polygenic HT however has proven to be more complex than the monogenic one, as it is 
hypothesized that effects on this case are multiple and additive. Advances in the field 
of GWAS have shone some light to many different pathophysiological pathways and 
the interaction among them. The full understanding of these pathways doesn’t seem 
possible in the near future, but research is ever advancing. The discovery of more and 
more significant loci and their function will enable creation of individual risk profiles 
and allow to identify concrete variants which would beneficiate from specific 
treatments. Findings up to today are believed to only represent less than 5% of blood 
pressure heritability by themselves, even if this percentage rises as we take into 
account learnt habits like or modifiable lifestyle factors such as alcohol consumption 
body mass index, smoking and educational level; it is still believed that huge progress 
can still be made in this field of research. The prospect for polygenic hypertension lies 
in identification of new loci, and application of known and yet know loci to identify 
individuals at risk of disease, for clinical guidance and management, causing a direct 
improvement in prognosis. 
 
Even though traditionally the etiology of essential hypertension has been attributed 
mostly to lifestyle and environmental factors, in the last decades the paradigm is 
shifting to a more genetic based approach, mostly thanks to advances in the field of 
GWAS. This represents one of the many pathways in which medicine could evolve to a 
more personalized and gene-based approach. 
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